Tangram Doses First Participant in TGM-148 Phase I Trial
Tangram says the first participant in its Phase I study of TGM-148, an investigational RNAi treatment for bleeding disorders, has received a first dose.
Tangram says the first participant in its Phase I study of TGM-148, an investigational RNAi treatment for bleeding disorders, has received a first dose.